A system for determining maximum tolerated dose in clinical trial

DOI10.1080/24754269.2021.1871708OpenAlexW3121830851MaRDI QIDQ5880093

Ying Ji, Min Wang, Keying Ye, Xiao-Bin Yang

Publication date: 7 March 2023

Published in: Statistical Theory and Related Fields (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1080/24754269.2021.1871708

zbMATH Keywords

Bayesian methodsphase I clinical trialcontinual reassessment method (CRM)maximum tolerated dose (MTD)Markov chain Monte Carlo (MCMC) methoddrug dose findingtoxicity responses

Mathematics Subject Classification ID

Statistics (62-XX)

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• On the consistency of the continual reassessment method with multiple toxicity constraints
• A phase I dose-finding study based on polychotomous toxicity responses
• Miscellanea. A stopping rule for the continual reassessment method
• Designs foe phase i cancer clinical trials with differentiation of graded toxicity
• Semiparametric Dose Finding Methods
• Estimating the Probability of Toxicity at the Recommended Dose Following a Phase I Clinical Trial in Cancer
• Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design
• A study of the probit model with latent variables in Phase I clinical trials
• The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
• Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
• Continual reassessment designs with early termination

This page was built for publication: A system for determining maximum tolerated dose in clinical trial